Handelsinvest Investeringsforvaltning Has $801,000 Stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Handelsinvest Investeringsforvaltning reduced its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 16.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,648 shares of the specialty pharmaceutical company’s stock after selling 1,264 shares during the quarter. Handelsinvest Investeringsforvaltning’s holdings in Jazz Pharmaceuticals were worth $801,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of the business. Envestnet Asset Management Inc. raised its stake in shares of Jazz Pharmaceuticals by 40.6% in the third quarter. Envestnet Asset Management Inc. now owns 61,463 shares of the specialty pharmaceutical company’s stock worth $7,956,000 after acquiring an additional 17,758 shares during the last quarter. Hsbc Holdings PLC acquired a new position in Jazz Pharmaceuticals during the 3rd quarter worth $249,000. Mariner LLC increased its stake in shares of Jazz Pharmaceuticals by 10.4% in the 3rd quarter. Mariner LLC now owns 8,037 shares of the specialty pharmaceutical company’s stock valued at $1,040,000 after buying an additional 757 shares during the period. Natixis Advisors L.P. raised its position in shares of Jazz Pharmaceuticals by 66.0% during the third quarter. Natixis Advisors L.P. now owns 28,115 shares of the specialty pharmaceutical company’s stock worth $3,640,000 after acquiring an additional 11,176 shares during the last quarter. Finally, Toronto Dominion Bank bought a new position in Jazz Pharmaceuticals in the third quarter valued at about $1,813,000. 89.14% of the stock is currently owned by institutional investors.

Insider Activity

In other news, EVP Neena M. Patil sold 5,000 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Friday, May 3rd. The stock was sold at an average price of $109.65, for a total transaction of $548,250.00. Following the completion of the transaction, the executive vice president now directly owns 36,629 shares in the company, valued at approximately $4,016,369.85. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 4.20% of the company’s stock.

Jazz Pharmaceuticals Stock Down 0.0 %

Shares of Jazz Pharmaceuticals stock opened at $105.05 on Wednesday. The firm has a market cap of $6.62 billion, a PE ratio of 21.67, a P/E/G ratio of 1.64 and a beta of 0.58. The business’s 50 day simple moving average is $108.80 and its 200 day simple moving average is $116.44. The company has a debt-to-equity ratio of 1.38, a quick ratio of 1.90 and a current ratio of 2.27. Jazz Pharmaceuticals plc has a 52-week low of $103.01 and a 52-week high of $146.70.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings data on Wednesday, May 1st. The specialty pharmaceutical company reported $1.98 EPS for the quarter, missing analysts’ consensus estimates of $3.53 by ($1.55). Jazz Pharmaceuticals had a return on equity of 27.86% and a net margin of 8.61%. The business had revenue of $901.98 million for the quarter, compared to analyst estimates of $938.99 million. On average, analysts predict that Jazz Pharmaceuticals plc will post 15.35 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on JAZZ shares. Piper Sandler raised their target price on shares of Jazz Pharmaceuticals from $171.00 to $188.00 and gave the company an “overweight” rating in a research note on Wednesday, March 20th. Barclays cut their price target on Jazz Pharmaceuticals from $230.00 to $200.00 and set an “overweight” rating on the stock in a research note on Friday, May 3rd. HC Wainwright reaffirmed a “buy” rating and set a $200.00 price objective on shares of Jazz Pharmaceuticals in a research note on Friday, May 3rd. UBS Group cut their target price on Jazz Pharmaceuticals from $117.00 to $113.00 and set a “neutral” rating on the stock in a research note on Tuesday. Finally, Stifel Nicolaus boosted their target price on Jazz Pharmaceuticals from $225.00 to $230.00 and gave the stock a “buy” rating in a research report on Friday, March 15th. Two equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $188.62.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.